Erlotinib and Leflunomide Disrupt 6‐Formylindolo[3,2‐ b ]Carbazole Metabolism and Sensitize Keratinocytes to UVA Radiation‐Induced Apoptosis
- 31 May 2026
- journal article
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 42 (4) , e70099
Abstract
Background/Purpose: Phototoxicity is a common adverse effect triggered by systemic or topical drug treatments. It is mainly caused by drug‐induced sensitization to UVA radiation, arising from either the drug's inherent photosensitizing potential or its interference with the metabolism of endogenous photosensitizers. A potent endogenous UVA sensitizer is 6‐formylindolo[3,2‐ b ]carbazole (FICZ), a tryptophan photoproduct formed in UVB‐irradiated epidermal cells. By sequentially activating the aryl hydrocarbon receptor signaling pathway and inducing cytochrome P450 (CYP) 1A1 expression, FICZ induces its own degradation. Recently, we reported that the BRAF inhibitor vemurafenib interferes with CYP1A1 activity and sensitizes keratinocytes to FICZ/UVA‐induced phototoxicity. Herein, we screened 12 clinical drugs, known to exhibit phototoxicity in patients, for their potential to interfere with the metabolism of (exogenous) FICZ and sensitize HaCaT keratinocytes to UVA‐induced phototoxicity. Methods: The UV–VIS absorption of the drugs was determined, and their effect on CYP1A1 activity and FICZ/UVA‐triggered apoptosis was assessed in immortalized and primary human keratinocytes using 7‐ethoxyresorufin‐O‐deethylase (EROD) and caspase‐3 activity assays. Moreover, the impact of the candidate drugs on the metabolic degradation of FICZ in cells (LC analysis) as well as on the generation of oxidative stress (MitoSOX assay, qPCR analyses) was investigated. Results: We identified two drugs, erlotinib and leflunomide, to sensitize human keratinocytes to FICZ/UVA‐induced apoptosis by inhibiting CYP1A1 activity. Moreover, both drugs attenuated the metabolic breakdown of FICZ, enhanced the FICZ/UVA‐triggered formation of mitochondrial superoxide anions, and increased heme oxygenase‐1 (HMOX1) transcript levels, indicative of antioxidant defense activation. Conclusion: Disruption of FICZ metabolism may contribute to the phototoxicity of drugs.Keywords
Funding Information
- Jürgen Manchot Stiftung
- Deutsche Forschungsgemeinschaft (ME 3401/2‐1)
- Deutsche Forschungsgemeinschaft (HA 7346/6‐1)
This publication has 40 references indexed in Scilit:
- Targeting both wild-type EGFR and its drug-resistant mutants with erlotinib-aptamer conjugatesEuropean Journal of Medicinal Chemistry, 2025
- Skin sensitizers enhance superoxide formation by polycyclic aromatic hydrocarbons via the aldo-keto reductase pathwayFree Radical Biology and Medicine, 2025
- Drug-Induced Photosensitivity—An Update: Culprit Drugs, Prevention and ManagementDrug Safety, 2019
- Enhancing anti-cancer activity of erlotinib by antibody conjugated nanofibrin - In vitro studies on lung adenocarcinoma cell linesMaterials Chemistry and Physics, 2019
- Aryl hydrocarbon receptor (AHR): “pioneer member” of the basic-helix/loop/helix per - Arnt - sim (bHLH/PAS) family of “sensors” of foreign and endogenous signalsProgress in Lipid Research, 2017
- Concentrations of Erlotinib in Tumor Tissue and Plasma in Non–Small-Cell Lung Cancer Patients After Neoadjuvant TherapyClinical Lung Cancer, 2015
- Activation of the aryl hydrocarbon receptor by the widely used Src family kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine (PP2)Archives of Toxicology, 2014
- Natural furocoumarins as inducers and inhibitors of cytochrome P450 1A1 in rat hepatocytesBiochemical Pharmacology, 2005
- Metabolic fate of the Ah receptor ligand 6-formylindolo[3,2-b]carbazoleChemico-Biological Interactions, 2004
- Identification of 3′-Methoxy-4′-nitroflavone as a Pure Aryl Hydrocarbon (Ah) Receptor Antagonist and Evidence for More Than One Form of the Nuclear Ah Receptor in MCF-7 Human Breast Cancer CellsArchives of Biochemistry and Biophysics, 1995